Chemed (NYSE:CHE) exceeds Q3 2026 expectations
Chemed reported Q3 2026 revenue of $690.9M, exceeding estimates by 0.9%. Adjusted EPS was $6.75, a 4.9% beat. EBITDA margin was 19.4%, up from last year. Operating margin improved to 14%, but free cash flow margin dropped to 0.8%. Sales volumes declined 99.1% year-on-year.
How this was made
The 30-second read
Why it matters
The earnings beat provides a fresh catalyst for short-term trading, with potential upside for the stock.
Market read
Earnings surprise may prompt immediate buying pressure.
What to watch
Free cash flow margin fell sharply, indicating cash generation concerns.
Background
Chemed (NYSE:CHE) posted Q3 2026 results with revenue of $690.9M versus $684.5M consensus and adjusted EPS of $6.75 versus $6.44 consensus.
Ticker impact
Chemed reported Q3 2026 results beating revenue and EPS estimates, with higher adjusted EBITDA and operating margin.
likely upside as market prices in the revenue and EPS beat
The beat on key metrics is fresh, primary information that can be acted on immediately.
Market effects
Healthcare services sector may see modest lift from Chemed's beat.
U.S. markets may see a small positive bias in related pharma stocks.
Limited to U.S. healthcare equities.
Counterpoint
Investors may question sustainability of margin expansion given declining sales volumes.
Key entities
- companyChemed
U.S.-listed healthcare services provider.
